Genocea Biosciences, Inc.

... ...
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 3.30%151.850.0%$2783.13m
BNGOBioNano Genomics, Inc. -2.94%12.210.0%$2518.37m
GILDGilead Sciences, Inc. -2.14%66.701.0%$655.34m
AMGNAmgen, Inc. 0.58%258.601.3%$584.65m
REGNRegeneron Pharmaceuticals, Inc. -0.75%544.102.7%$497.98m
ALXNAlexion Pharmaceuticals, Inc. 0.27%161.752.0%$475.34m
CRSPCRISPR Therapeutics AG -6.46%169.530.6%$445.57m
ILMNIllumina, Inc. -0.11%420.553.5%$443.81m
NVAXNovavax, Inc. -3.27%127.1692.9%$407.11m
VRTXVertex Pharmaceuticals, Inc. -1.52%237.641.9%$379.54m
SRPTSarepta Therapeutics, Inc. -3.60%92.6513.8%$343.41m
BIIBBiogen, Inc. -1.41%271.671.7%$323.61m
BNTXBioNTech SE -3.91%106.290.0%$307.94m
EXASEXACT Sciences Corp. -8.37%141.0419.6%$251.66m
PACBPacific Biosciences of California, Inc. -8.54%32.887.4%$199.92m

Company Profile

Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.